ClinicalTrials.gg
CompletedNCT06475846Updated Jan 20, 2025

A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

A Phase 2 interventional study of HRS5580 and HRS5580 in Preventing of Postoperative Nausea and Vomiting in Adults, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Postoperative Nausea and Vomiting with a site in China — 14 open to participants now, 15 under way, none of them phase 3. Postoperative Nausea and Vomiting · China.

Enrollment
17th of 44
235 · median 200
Started
2024
with 9 others
Phase 2
2 of 56
none open now
Registered
40th of 56
by date

Among the 56 studies in Postoperative Nausea and Vomiting with a site in China, this one is the 17th largest by enrollment of the 44 interventional ones that give a count, is one of 10 that started in 2024, is one of 2 in phase 2, and was the 40th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

14 of the 56 studies in Postoperative Nausea and Vomiting with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Postoperative Nausea and Vomiting with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.

03

Conditions studied

  • Preventing of Postoperative Nausea and Vomiting in Adults
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Plan to undergo elective surgery under general anesthesia;
  3. ≥18 years old
  4. Meet the weight standard
  5. Conform to the ASA Physical Status Classification
  6. Expected postoperative hospital stay ≥72 hours
  7. PONV risk factors ≥3

Exclusion criteria

Exclusion Criteria:

  1. Subjects with vomiting and/or retching and nausea occurred before surgery
  2. Subjects with a history of vestibular disease, central nervous system and other system diseases
  3. Subjects with a previous history of chronic nausea or vomiting/retching
  4. Subjects with a history of myocardial infarction or unstable angina pectoris
  5. Subjects with atrioventricular block or cardiac insufficiency
  6. Subjects with a history of ischemic stroke or
  7. Subjects with poor blood pressure control after medication
  8. Abnormal
  9. Abnormal values in the laboratory
  10. Allergic to a drug ingredient or component
  11. Received treatment with potential antiemetic effects before starting the product
  12. Subjects who received chemotherapy prior to surgery
  13. Use of drugs that affect the antiemetic effect, and the time between the last use of the test drug and the start of the time is less than 5 half-lives
  14. Plan to receive local anesthesia only or total intravenous anesthesia only
  15. Subjects who are expected to require an in-situ nasogastric tube or orogastric tube after completion of surgery
  16. Subjects expected to be transferred to the ICU at the end of surgery
  17. Pregnant or nursing women
  18. No during the specified period of time
  19. Participated in clinical trials of other drugs (received experimental drugs)
  20. The inestigators determined that other conditions were inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    Treatment group A: HRS5580

    Drug: HRS5580

  • Experimental
    Treatment group B: HRS5580

    Drug: HRS5580

  • Experimental
    Treatment group C: HRS5580

    Drug: HRS5580

  • Active comparator
    Treatment group D: Ondansetron

    Drug: Ondansetron

  • Placebo comparator
    Treatment group E: blank preparation.

    Drug: blank preparation

Interventions

  • DrugHRS5580

    HRS5580; low dose

  • DrugHRS5580

    HRS5580; middle dose

  • DrugHRS5580

    HRS5580; middle dose

  • Ondansetron

  • Drugblank preparation

    blank preparation.

06

What researchers measure

Primary outcomes

  1. No vomiting rate within 72 hours after extubation

    Time frame: at 72 hours after extubation

Secondary outcomes

  1. Complete response rate (defined as the proportion of subjects without vomiting and receiving no rescue therapy) at 24, 48, 72, 96, and 120 hours after extubation

    Time frame: at24, 48, 72, 96, and 120 hours after extubation

  2. No vomiting at 24, 48, 96, and 120 hours after extubation,

    Time frame: at 24, 48, 96, and 120 hours after extubation

  3. Proportion of subjects who did not experience significant nausea within 24, 48, 72, 96, and 120 hours after extubation

    Time frame: at 24, 48, 72, 96, and 120 hours after extubation

  4. Proportion of participants not receiving rescue medication within 24, 48, 72, 96, and 120 hours of extubation

    Time frame: at 24, 48, 72, 96, and 120 hours of extubation

07

Study locations

2 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Oct 2024, 4 months.

Of 17 phase 2 interventional studies under Postoperative Nausea and Vomiting, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 29. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 26, 2024
StartActual
Jun 25, 2024
Primary completionActual
Oct 29, 2024
CompletionActual
Oct 29, 2024
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06475846
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Jun 25, 2024
Primary completion
Oct 29, 2024
Completion
Oct 29, 2024
Last update
Jan 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion